ASPEN PHARMACARE HOLDINGS LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 220.7 ZAR | +1.98% |
|
+1.70% | +8.46% |
| Mar. 08 | Aspen Pharmacare Holdings Limited Announces Board Changes | CI |
| Mar. 05 | Aspen Pharmacare Holdings Limited Seeks Acquisitions | CI |
| Sales 2024 * | 44.56B 0 | Sales 2025 * | 50.72B 0 | Capitalization | 98.2B 0 |
|---|---|---|---|---|---|
| Net income 2024 * | 6.23B - | Net income 2025 * | 8.46B - | EV / Sales 2024 * | 2.7 x |
| Net Debt 2024 * | 21.9B 0 | Net Debt 2025 * | 19.08B 0 | EV / Sales 2025 * | 2.31 x |
| P/E ratio 2024 * |
16.8
x | P/E ratio 2025 * |
11.7
x | Employees | 8,887 |
| Yield 2024 * |
1.66% | Yield 2025 * |
2.07% | Free-Float | 60.05% |
More Fundamentals
* Assessed data
More news
Latest transcript on Aspen Pharmacare Holdings Limited
More press releases
| 1 day | +1.98% | ||
| 1 week | +1.70% | ||
| Current month | +0.61% | ||
| 1 month | +0.90% | ||
| 3 months | +9.94% | ||
| 6 months | +32.95% | ||
| Current year | +8.46% |
1 week
210.00
221.28
1 month
210.00224.99
Current year
185.41224.99
1 year
160.96224.99
3 years
128.89281.67
5 years
64.07281.67
10 years
64.07448.68
| Managers | Title | Age | Since |
|---|---|---|---|
Stephen Saad
FOU | Founder | 60 | - |
Sean Capazorio
DFI | Director of Finance/CFO | 57 | 98-12-31 |
| Chief Operating Officer | 60 | 98-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 98-12-31 | |
Stephen Saad
FOU | Founder | 60 | - |
Kuseni Dlamini
CHM | Chairman | 53 | 12-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.49% | 2 M€ | -14.14% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 220.7 | +1.98% | 898,244 |
| 24-04-25 | 216.4 | +0.06% | 570,723 |
| 24-04-24 | 216.3 | +1.20% | 1,267,616 |
| 24-04-23 | 213.7 | -1.38% | 1,012,338 |
| 24-04-22 | 216.7 | -0.13% | 1,127,287 |
End-of-day quote Johannesburg S.E., April 25, 2024
More quotes
Aspen Pharmacare Holdings Limited is the African leading pharmaceutical group. The group's products are primarily for the treatment of asthma, HIV, bacterial infections, gastro-intestinal, respiratory and inflammatory diseases. Net sales break down by family of products as follows:
- pharmaceuticals (71.6%): anaesthetics products, thrombosis products, cytotoxic products, etc.;
- other (28.4%): infant nutrition products and consumer products.
At the end of June 2022, the group had 16 production sites worldwide.
Sector
Pharmaceuticals
Calendar
2024-09-02
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
220.7
ZAR
Average target price
232
ZAR
Spread / Average Target
+5.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.46% | 5.22B | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| -4.29% | 4.71B |
- Stock Market
- Equities
- APN Stock
